FDA Approves Sparsentan as First FSGS Treatment

(MedPage Today) -- The FDA expanded the indication of sparsentan (Filspari) to make it the first treatment for focal segmental glomerulosclerosis (FSGS), developer Travere Therapeutics announced on Monday. A once-daily oral tablet, sparsentan...
Source
MedPage Today
Opens original article in a new tab



